Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Could the volume here get any lower???????

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Nov 04, 2022 8:40pm

186 Views

Post# 35074979

RE:RE:Could the volume here get any lower???????

I was looking at GOBLET from my lay perspective; that is to say with very little understanding of trials.
Any of the four cohorts showing an ORR (overall response rate) above a prespecified threshold in Stage 1 (defined as achieving a minimum number of radiologic responses by week 16) may be advanced to Stage 2 and enroll additional patients.

We know there are 27 out of 55 enrolled.

Can we infer anything further given the above.

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for Oct. 1, 2024